Loading filters...
Publications per Year (1832 total)
14
1990
18
·
17
·
20
·
16
·
22
1995
10
·
30
·
35
·
33
·
38
2000
40
·
39
·
34
·
46
·
61
2005
52
·
66
·
55
·
66
·
69
2010
70
·
91
·
62
·
75
·
81
2015
69
·
63
·
63
·
65
·
65
2020
78
·
66
·
73
·
52
·
60
2025
18
·
Loaded
Click to load
50 / 1832 papers loaded(scroll for more)
202618 papers
Ewing SarcomaAdvanced/Metastatic2026
Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.
Gatz SA et al. Clin Cancer Res. 2026
Ewing SarcomaAll Stages2026
Multicenter Histology Image Integration and Multiscale Deep Learning Support Machine Learning-Enabled Pediatric Sarcoma Classification.
Thiesen AH et al. Cancer Res. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group.
D'Ambrosio L et al. Ann Oncol. 2026
Ewing SarcomaAll Stages2026
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.
Moura DS et al. Clin Cancer Res. 2026
LiposarcomaAll Stages2026
Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.
Babatunde OO et al. ESMO Open. 2026
Ewing SarcomaAll Stages2026
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.
Bernadette B et al. Br J Cancer. 2026
Ewing SarcomaAll Stages2026
FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.
Gracilla DE et al. Cancer Res. 2026
LiposarcomaAll Stages2026
Targeting the Non-Homologous End-Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence.
Jalving T et al. Cancer Res. 2026
Soft Tissue SarcomaAll Stages2026
Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.
Baldi GG et al. Eur J Cancer. 2026
Soft Tissue SarcomaAll Stages2026
Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network.
Baldi GG et al. ESMO Open. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial.
Zhao JK et al. Clin Cancer Res. 2026
LiposarcomaAll Stages2026
Vascular Reconstruction in Extremity Soft Tissue Sarcomas: A Systematic Review and Single-Arm Meta-Analysis.
Delgado LM et al. J Surg Oncol. 2026
OsteosarcomaAll Stages2026
Spermidine Secreted by Apoptotic Cells Enhances Chemotherapy Resistance by Modulating β-Catenin Activity in Osteosarcoma.
Yu Q et al. Clin Cancer Res. 2026
GISTAdvanced/Metastatic2026
Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming.
Li C et al. Cancer Res. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma.
Yun KH et al. Clin Cancer Res. 2026
Ewing SarcomaAdvanced/Metastatic2026
Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial.
Laurence V et al. Br J Cancer. 2026
Soft Tissue SarcomaAdvanced/Metastatic2026
Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907).
Kojima Y et al. Eur J Cancer. 2026
LiposarcomaAll Stages2026
Pancreaticoduodenectomy and IVC resection in retroperitoneal sarcoma: Expanding the limits of feasible surgery.
Benuzzi L et al. Eur J Surg Oncol. 2026
202532 papers
LiposarcomaAll Stages2025
The Impact of Perioperative Radiotherapy on Disease-Specific Survival in Patients with Localized Retroperitoneal Liposarcoma: A Population-Based Propensity-Score Matched Analysis.
Wilhelm A et al. Ann Surg Oncol. 2025
LiposarcomaAll Stages2025
Neoadjuvant Immunotherapy for Resectable Dedifferentiated Liposarcoma: A National Cohort Analysis.
Farooq MS et al. J Surg Oncol. 2025
Liposarcomaearly2025
Sarcoma: Last Year's Practice Changing Papers.
van Houdt WJ et al. Ann Surg Oncol. 2025
Liposarcomaearly2025
Radiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Collaboration.
van der Burg SJC et al. Ann Surg Oncol. 2025
Liposarcomaearly2025
ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk.
Callegaro D et al. Ann Surg Oncol. 2025
LiposarcomaAll Stages2025
Six Surgical Stages in the Resection of Primary Left Retroperitoneal Liposarcoma: A Standardized Comprehensive Approach.
Baia M et al. Ann Surg Oncol. 2025
Liposarcomaearly2025
Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease.
Fine SA et al. J Surg Oncol. 2025
Liposarcomaearly2025
Temporospatial Recurrence Patterns and Predictive Factors for Recurrences in 984 Patients With Adult Soft Tissue Sarcomas.
Deo S et al. J Surg Oncol. 2025
LiposarcomaAdvanced/Metastatic2025
A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer.
Zhang J et al. ESMO Open. 2025
LiposarcomaAll Stages2025
Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing.
Vanacker H et al. ESMO Open. 2025
LiposarcomaAdvanced/Metastatic2025
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
D'Angelo SP et al. J Clin Oncol. 2025
LiposarcomaAdvanced/Metastatic2025
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma.
van der Laan P et al. ESMO Open. 2025
LiposarcomaAll Stages2025
Characterizing the Transformation and Diagnosis of Atypical Lipomatous Tumor to Dedifferentiated Liposarcoma: Single Institutional Outcomes.
Butler Z et al. J Surg Oncol. 2025
LiposarcomaAdvanced/Metastatic2025
An onco-vascular surgical approach: Internal iliac artery transposition for external iliac artery repair during cytoreductive surgery.
Altınsoy E et al. Eur J Surg Oncol. 2025
Soft Tissue Sarcomaearly2025
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
Vanzulli A et al. ESMO Open. 2025
LiposarcomaAdvanced/Metastatic2025
Immunocompetent Murine Models Recapitulate the Heterogeneous Tumor-Immune Microenvironment of Human Liposarcoma.
Shafer AM et al. Clin Cancer Res. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial.
Penel N et al. Ann Oncol. 2025
GISTAdvanced/Metastatic2025
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial.
Yip D et al. Br J Cancer. 2025
GISTearly2025
Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.
Cuvelier C et al. ESMO Open. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.
Wilky BA et al. Clin Cancer Res. 2025
LiposarcomaAll Stages2025
Cumulative incidence and survival outcomes of brain metastases in sarcoma: a large single center retrospective analysis.
Erjan A et al. Br J Cancer. 2025
GISTearly2025
A Systematic Review with a Demonstrative Case of KIT and DOG-1 Expressing Gastrointestinal Stromal Tumors Harboring ETV6-NTRK3 Fusions.
Ranjbarian T et al. Clin Cancer Res. 2025
GISTAdvanced/Metastatic2025
AT101 Suppresses Gastrointestinal Stromal Tumor Growth and Promotes Apoptosis via YAP/TAZ-CCND1 and FBXW7-MCL1 Axes.
Wu X et al. Ann Surg Oncol. 2025
GISTAll Stages2025
Intratumoral Bacteria are Uncommon in Gastrointestinal Stromal Tumor.
Tardy KJ et al. Ann Surg Oncol. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.
Siontis BL et al. Clin Cancer Res. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
Ribociclib in Sequential Combination with Doxorubicin in Anthracycline-Naïve Advanced Soft-Tissue Sarcomas: Results of a Dose-Finding Phase Ib Study.
Davis LE et al. Clin Cancer Res. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
Ossifying fibromyxoid tumours: A case series.
Pozas J et al. Eur J Cancer. 2025
Soft Tissue SarcomaAdvanced/Metastatic2025
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma.
Casanova M et al. ESMO Open. 2025
LiposarcomaAll Stages2025
Evaluation of Diagnostic Accuracy of Preoperative CT-Based Radiomics in Primary Retroperitoneal Sarcoma.
Tirotta F et al. Ann Surg Oncol. 2025
LiposarcomaAll Stages2025
Characterizing Socioeconomic Factors That Influence Treatment Selection in Myxoid Liposarcoma: A Population-Based Study From the Surveillance, Epidemiology, and End Results Database.
Joachim K et al. J Surg Oncol. 2025
LiposarcomaAll Stages2025
Combined Laparoscopic and Open Surgical Approach for Well Differentiated Trans-compartmental Liposarcoma Between Pelvic and Femoral Regions.
Aulicino M et al. Ann Surg Oncol. 2025
GISTAdvanced/Metastatic2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
Heinrich MC et al. J Clin Oncol. 2025